Literature DB >> 33499725

Bone mesenchymal stem cell-derived extracellular vesicles promote the repair of intervertebral disc degeneration by transferring microRNA-199a.

Tao Wen1, Hongshen Wang1, Yongjin Li1, Yongpeng Lin1, Shuai Zhao1, Jinggong Liu1, Bolai Chen1.   

Abstract

Extracellular vesicles (EVs) secreted by bone marrow mesenchymal stem cells (BMSCs) protect intervertebral disc degeneration (IDD) by regulating nucleus pulposus cell (NPC) apoptosis. But the mechanism of BMSCs-EVs-microRNA (miR)-199a in IDD remains unclear. In this study, after the acquisition and identification of BMSCs and BMSCs-EVs, IDD mouse model was established and treated with BMSCs-EVs. The pathological changes of NPCs, positive expression of MMP-2, MMP-6 and TIMP1, and the senescence and apoptosis of NPCs were evaluated. Microarray analysis was employed to analyze the differentially expressed miRs and genes after EV treatment. NPCs were treated with EVs/miR-199a/TGF-β agonist SRI-011381. The positive expression of col II and Aggrecan was assessed. The target gene and downstream pathway of miR-199a were analyzed. In vivo experiment, after BMSCs-EV treatment, MMP-2, MMP-6, TIMP1 and TUNEL-positive cells in IDD mice were decreased, and miR-199a was increased. In vitro experiments, the expression of col Ⅱ and Aggrecan, SA-β gal positive cells and apoptosis rate of NPCs were decreased after EV intervention. The protective effect of BMSCs-EVs on NPCs was impaired by reducing miR-199a carried by EVs. miR-199a could target GREM1 to inactivate the TGF-β pathway. miR-199a carried by BMSCs-EVs promotes IDD repair by targeting GREM1 and downregulating the TGF-β pathway. Our work confers a promising therapeutic strategy for IDD.

Entities:  

Keywords:  GREM1; Intervertebral disc degeneration; TGF-β signaling pathway; bone mesenchymal stem cells; extracellular vesicles; miR-199a; nucleus pulposus cells

Mesh:

Substances:

Year:  2021        PMID: 33499725      PMCID: PMC7889239          DOI: 10.1080/15384101.2020.1863682

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  43 in total

Review 1.  TGF-β signaling in intervertebral disc health and disease.

Authors:  S Chen; S Liu; K Ma; L Zhao; H Lin; Z Shao
Journal:  Osteoarthritis Cartilage       Date:  2019-05-24       Impact factor: 6.576

Review 2.  Mesenchymal stem cell exosomes.

Authors:  Ruenn Chai Lai; Ronne Wee Yeh Yeo; Sai Kiang Lim
Journal:  Semin Cell Dev Biol       Date:  2015-03-09       Impact factor: 7.727

3.  The noncoding RNA linc-ADAMTS5 cooperates with RREB1 to protect from intervertebral disc degeneration through inhibiting ADAMTS5 expression.

Authors:  Kun Wang; Yu Song; Wei Liu; Xinghuo Wu; Yukun Zhang; Shuai Li; Liang Kang; Ji Tu; Kangcheng Zhao; Wenbin Hua; Cao Yang
Journal:  Clin Sci (Lond)       Date:  2017-03-24       Impact factor: 6.124

Review 4.  Mechanobiology of annulus fibrosus and nucleus pulposus cells in intervertebral discs.

Authors:  Sara Molladavoodi; John McMorran; Diane Gregory
Journal:  Cell Tissue Res       Date:  2019-12-17       Impact factor: 5.249

5.  Anticonvulsants in the treatment of low back pain and lumbar radicular pain: a systematic review and meta-analysis.

Authors:  Oliver Enke; Heather A New; Charles H New; Stephanie Mathieson; Andrew J McLachlan; Jane Latimer; Christopher G Maher; C-W Christine Lin
Journal:  CMAJ       Date:  2018-07-03       Impact factor: 8.262

Review 6.  Immunoregulation by mesenchymal stem cells: biological aspects and clinical applications.

Authors:  Marta E Castro-Manrreza; Juan J Montesinos
Journal:  J Immunol Res       Date:  2015-04-19       Impact factor: 4.818

7.  Mesenchymal stem cells deliver exogenous miR-21 via exosomes to inhibit nucleus pulposus cell apoptosis and reduce intervertebral disc degeneration.

Authors:  Xiaofei Cheng; Guoying Zhang; Liang Zhang; Ying Hu; Kai Zhang; Xiaojiang Sun; Changqing Zhao; Hua Li; Yan Michael Li; Jie Zhao
Journal:  J Cell Mol Med       Date:  2017-08-14       Impact factor: 5.310

8.  Dimethyloxaloylglycine-stimulated human bone marrow mesenchymal stem cell-derived exosomes enhance bone regeneration through angiogenesis by targeting the AKT/mTOR pathway.

Authors:  Bo Liang; Jia-Ming Liang; Jia-Ning Ding; Jia Xu; Jian-Guang Xu; Yi-Min Chai
Journal:  Stem Cell Res Ther       Date:  2019-11-20       Impact factor: 6.832

9.  Extracellular vesicles from human liver stem cells inhibit renal cancer stem cell-derived tumor growth in vitro and in vivo.

Authors:  Alessia Brossa; Valentina Fonsato; Cristina Grange; Stefania Tritta; Marta Tapparo; Ruggero Calvetti; Massimo Cedrino; Sofia Fallo; Paolo Gontero; Giovanni Camussi; Benedetta Bussolati
Journal:  Int J Cancer       Date:  2020-02-25       Impact factor: 7.396

10.  Preclinical development of a microRNA-based therapy for intervertebral disc degeneration.

Authors:  Ming-Liang Ji; Hua Jiang; Xue-Jun Zhang; Pei-Liang Shi; Chao Li; Hao Wu; Xiao-Tao Wu; Yun-Tao Wang; Chen Wang; Jun Lu
Journal:  Nat Commun       Date:  2018-11-28       Impact factor: 14.919

View more
  10 in total

1.  circ_0072464 Shuttled by Bone Mesenchymal Stem Cell-Secreted Extracellular Vesicles Inhibits Nucleus Pulposus Cell Ferroptosis to Relieve Intervertebral Disc Degeneration.

Authors:  Xiaojun Yu; Haoran Xu; Qikun Liu; Yingguang Wang; Shanxi Wang; Rui Lu; Yongqiao Jiang; Hao Kang; Weihua Hu
Journal:  Oxid Med Cell Longev       Date:  2022-06-29       Impact factor: 7.310

2.  Bone Marrow Mesenchymal Stem Cell-Derived Extracellular Vesicles Carrying circ_0050205 Attenuate Intervertebral Disc Degeneration.

Authors:  Xiao-Jun Yu; Qi-Kun Liu; Rui Lu; Shan-Xi Wang; Hao-Ran Xu; Ying-Guang Wang; Yuan Bao; Yong-Qiao Jiang; Meng-Wei Li; Hao Kang
Journal:  Oxid Med Cell Longev       Date:  2022-07-05       Impact factor: 7.310

Review 3.  Extracellular Vesicles as an Emerging Treatment Option for Intervertebral Disc Degeneration: Therapeutic Potential, Translational Pathways, and Regulatory Considerations.

Authors:  Tyler J DiStefano; Keti Vaso; George Danias; Henry N Chionuma; Jennifer R Weiser; James C Iatridis
Journal:  Adv Healthc Mater       Date:  2021-07-23       Impact factor: 9.933

Review 4.  Extracellular Vesicles Derived From Stem Cells in Intervertebral Disc Degeneration.

Authors:  Xinjie Wu; Wei Sun
Journal:  Front Cell Dev Biol       Date:  2022-01-13

Review 5.  Mesenchymal Stem Cell-Derived Exosomes as a Novel Strategy for the Treatment of Intervertebral Disc Degeneration.

Authors:  Lin Lu; Aoshuang Xu; Fei Gao; Chenjun Tian; Honglin Wang; Jiayao Zhang; Yi Xie; Pengran Liu; Songxiang Liu; Cao Yang; Zhewei Ye; Xinghuo Wu
Journal:  Front Cell Dev Biol       Date:  2022-01-24

6.  Grem1 accelerates nucleus pulposus cell apoptosis and intervertebral disc degeneration by inhibiting TGF-β-mediated Smad2/3 phosphorylation.

Authors:  Shunlun Chen; Linchuan Lei; Zemin Li; Fan Chen; Yuming Huang; Guowei Jiang; Xingyu Guo; Zhuoyang Zhao; Hui Liu; Hua Wang; Caijun Liu; Zhaomin Zheng; Jianru Wang
Journal:  Exp Mol Med       Date:  2022-04-19       Impact factor: 12.153

Review 7.  Mesenchymal Stem Cell-Derived Exosomes and Intervertebral Disc Regeneration: Review.

Authors:  Basanta Bhujel; Hae-Eun Shin; Dong-Jun Choi; Inbo Han
Journal:  Int J Mol Sci       Date:  2022-06-30       Impact factor: 6.208

Review 8.  Exosomes and exosomal miRNAs: A new therapy for intervertebral disc degeneration.

Authors:  Zhichao Li; Yan Wu; Guoqing Tan; Zhanwang Xu; Haipeng Xue
Journal:  Front Pharmacol       Date:  2022-09-08       Impact factor: 5.988

9.  miR-3960 from Mesenchymal Stem Cell-Derived Extracellular Vesicles Inactivates SDC1/Wnt/β-Catenin Axis to Relieve Chondrocyte Injury in Osteoarthritis by Targeting PHLDA2.

Authors:  Peng Ye; Zhanhu Mi; Daihao Wei; Pengcheng Gao; Mei Ma; Haibo Yang
Journal:  Stem Cells Int       Date:  2022-08-25       Impact factor: 5.131

Review 10.  Insights into Exosome in the Intervertebral Disc: Emerging Role for Disc Homeostasis and Normal Function.

Authors:  Xin Zhao; Benchi Xu; Wei Duan; Le Chang; Rui Tan; Zhen Sun; Zhengxu Ye
Journal:  Int J Med Sci       Date:  2022-09-25       Impact factor: 3.642

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.